Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space [Seeking Alpha]
Xilio Therapeutics, Inc. (XLO)
Company Research
Source: Seeking Alpha
Xilio Therapeutics out-licensed their modified IL-12 to Gilead, but I wouldn't be surprised if Werewolf Therapeutics also has a competitive modified IL-12, with WTX-330. Werewolf Therapeutics is reporting data from its clinical trials of WTX-124 and WTX-330 this half (H1'24), providing near-term catalysts. Werewolf Therapeutics, Inc. NASDAQ: HOWL ) develops modified cytokines, called Indukines, with potential to treat cancer. I rated HOWL a strong buy back in December 2023, based on encouraging data seen with their modified interleukin-2 (IL-2), WTX-124, the potential of the rest of the pipeline and their cash-efficient operation. There is a near-term readout from a major competitor, Medicenna Therapeutics Corp. ( OTCQB:MDNAF , I'm long), and there has been business development in the cytokine space too, with Gilead Sciences, Inc. ( GILD ) in-licensing Xilio Therapeutics, Inc. ( XLO ), modified interleukin-12 (IL-12). The competition is thus ever present, a major competitor reado
Show less
Read more
Impact Snapshot
Event Time:
XLO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XLO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XLO alerts
High impacting Xilio Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
XLO
News
- Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]Yahoo! Finance
- Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewswire
- Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care ConferenceGlobeNewswire
- Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology ConferenceGlobeNewswire
XLO
Sec Filings
- 4/25/24 - Form ARS
- 4/25/24 - Form DEFA14A
- 4/25/24 - Form DEF
- XLO's page on the SEC website